DOCSLIB.ORG

Treatment of Atypical Depression with Cognitive Therapy Or Phenelzine a Double-Blind, Placebo-Controlled Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment of Atypical Depression with Cognitive Therapy Or Phenelzine a Double-Blind, Placebo-Controlled Trial ORIGINAL ARTICLE Treatment of Atypical Depression With Cognitive Therapy or Phenelzine A Double-blind, Placebo-Controlled Trial Robin B. Jarrett, PhD; Martin Schaffer, MD; Donald McIntire, PhD; Amy Witt-Browder, MA; Dolores Kraft, PhD; Richard C. Risser, MS Background: Patients with atypical depression are more Results: With the use of an intention-to-treat strategy, likely to respond to monoamine oxidase inhibitors than the response rates (21-item Hamilton Rating Scale for De- to tricyclic antidepressants. They are frequently offered pression score, #9) were significantly greater after cog- psychotherapy in the absence of controlled tests. There nitive therapy (58%) and phenelzine (58%) than after pill are no prospective, randomized, controlled trials, to our placebo (28%). Phenelzine and cognitive therapy also re- knowledge, of psychotherapy for atypical depression or duced symptoms significantly more than placebo accord- of cognitive therapy compared with a monoamine oxi- ing to contrasts after a repeated-measures analysis of co- dase inhibitor. Since there is only 1 placebo-controlled variance and random regression with the use of the blind trial of cognitive therapy, this trial fills a gap in the lit- evaluator’s final Hamilton Rating Scale for Depression score. erature on psychotherapy for depression. The scores between cognitive therapy and phenelzine did not differ significantly. Supplemental analyses of other Methods: Outpatients with DSM-III-R major depres- symptom severity measures confirm the finding. sive disorder and atypical features (N = 108) were treated in a 10-week, double-blind, randomized, controlled trial Conclusions: Cognitive therapy may offer an effective comparing acute-phase cognitive therapy or clinical man- alternative to standard acute-phase treatment with a agement plus either phenelzine sulfate or placebo. Atypi- monoamine oxidase inhibitor for outpatients with ma- cal features were defined as reactive mood plus at least 2 jor depressive disorder and atypical features. additional symptoms: hypersomnia, hyperphagia, leaden paralysis, or lifetime sensitivity to rejection. Arch Gen Psychiatry. 1999;56:431-437 ATIENTS WITH majordepressive than waiting-list controls,15 has not dif- disorder (MDD) and atypical fered significantly from antidepressant features have shown a prefer- medication used alone,12,16-19 and may not ential response to phenelzine differ when combined with pharmaco- sulfate compared with imipra- therapy.12,19,20 mine hydrochloride in placebo-controlled We defined atypical features as a sub- P1-7 trials, prompting the recommendation of type of MDD during which patients have monoamine oxidase inhibitors (MAOIs) as reactive mood and at least 2 of the follow- the standard of care.8 Unfortunately, MAOIs ing 4 symptoms: hyperphagia, hypersom- have dietary restrictions, contraindications, nia, leaden paralysis, or a lifetime history and well-known side effects.3,9 Although Re- of interpersonal sensitivity to rejection, re- imherr et al10 and Pande et al11 showed that sulting in functional impairment. This de- fluoxetine hydrochloride may offer an al- finition is comparable with that used in ternative, many patients cannot or will not DSM-IV21 and has heuristic value in select- take antidepressant medication. Since psy- ing patients who respond to phenelzine. chosocial treatments are sought by and pre- The purpose of this double-blind, pla- scribed for depressed patients with atypical cebo-controlled trial of outpatients with features, studies of efficacy and effectiveness MDD and atypical features was to com- are needed. pare acute-phase cognitive therapy with Cognitive therapy is effective for some the standard of care, phenelzine. Phenel- patients with MDD.12,13 Mercier and col- zine was selected instead of a selective se- leagues14 showed that cognitive therapy re- rotonin reuptake inhibitor because there From the Department of duced symptoms of depressed outpa- is more support for its efficacy in this pa- 1-7 Psychiatry, The University of tients with atypical features. In depressed tient population. We hypothesized that Texas Southwestern Medical outpatients who were not subtyped, acute- cognitive therapy and phenelzine would Center at Dallas. phase cognitive therapy is more effective each reduce depressive symptoms signifi- ARCH GEN PSYCHIATRY/ VOL 56, MAY 1999 431 ©1999 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 PATIENTS AND METHODS Of the 366 patients studied, 287 (78.4%) were diagnosed as having MDD; of the patients with MDD, 242 (66.1% of those studied) were also diagnosed as having atypical de- PATIENTS pression. One hundred eighty-one (49.5%) were eligible. Thirty-nine (21.5%) refused consent (generally because of The protocol was approved by the institutional review scheduling problems or the desire to receive or avoid a study board. Subjects (recruited through media, printed treatment). The nonspecific treatment baseline (designed announcements, and self or practitioner referrals) under- to identify and exclude patients who respond to early, non- went triage by telephone. Outpatients (N = 366) with the specific effects) was initiated when patients signed consent complaint of depression participated in the Structured (n = 142). Subjects participated in 2 sessions (during 14 days) Clinical Interview for DSM-III-R (Outpatient Version),22 of nonspecific treatment by watching a videotape on mood which uses the DSM-III-R23 criteria for MDD and other disorders and reporting on symptoms from the HRSD-21. disorders. To assess MDD with atypical features, the At the end of nonspecific treatment, 13 patients had responded Atypical Depression Diagnostic Scale (Jonathan W. Stew- (ie, HRSD-21 ,14 or no MDD) and were referred. art, MD, written communication, October 20, 1988, and Final eligibility for randomization was evaluated by March 20, 1990) was administered for the initial episode. confirming that the inclusion criteria were met. One hun- If the diagnosis was absent at the nadir, symptoms were dred eight (76.0% of the consenting and eligible) patients reassessed at “any other time during the episode.” Criteria were randomized (Table 1) under the supervision of the (according to the Atypical Depression Diagnostic Scale) statistician (D.M.), who kept research personnel blind to for depression with atypical features included (1) main- assignment (phenelzine or placebo) during the study. tains reactive mood and (2) shows 2 or more of the fol- lowing: (a) increased appetite or weight gain; (b) over- TREATMENT PROCEDURES sleeping; (c) sensation of leaden paralysis or extreme heaviness of arms or legs, while depressed; and (d) life- Cognitive Therapy time sensitivity to interpersonal rejection.1,2 Diagnoses were confirmed by a faculty-level diagnos- Cognitive therapy was conducted as described by Beck et tician at a follow-up interview. Entry criteria were (1) DSM- al29 for 10 weeks, in 20 individual sessions held twice weekly. III-R MDD, (2) definite atypical depression, and (3) score Three experienced male therapists provided cognitive of 14 or more on the 21-item Hamilton Rating Scale for De- therapy. Two were doctoral-level clinical psychologists and pression (HRSD-21)24 at the initial or follow-up inter- 1 was a psychiatrist. An offsite consultant (see acknowl- view. All patients provided a medical history and a physi- edgments) used the Cognitive Therapy Scale30,31 to evalu- cian reviewed laboratory screening. ate competence and provide feedback to therapists and in- Patients were excluded if they (1) had a concurrent vestigators. medical disorder or treatment that might cause depressive Therapists participated in weekly group supervision. symptoms or required medication incompatible with Of 64 total Cognitive Therapy Scale ratings (ie, 2 planned MAOIs; (2) refused to be randomized or to maintain a ty- per patient), 9 (14%) received scores of less than 40. The ramine-free diet; (3) had other current primary comorbid grand mean Cognitive Therapy Scale score across all thera- psychiatric disorders (eg, organic mental disorders, psy- pists was 46.1 ± 4.1. The analyses of variance showed no chotic disorders, schizophrenia, schizoaffective disorders, statistically significant differences in the mean Cognitive alcoholism, or drug abuse or dependency in the last 6 Therapy Scale scores among therapists (F2 = 2.50; P = .09) months); (4) scored less than 14 on the HRSD-21 at diag- or across years (F4 = 1.40; P = .24). nostic evaluation and follow-up, or before randomization (see description of nonspecific treatment below); (5) could Phenelzine and Placebo not complete questionnaires; (6) represented an immi- nent suicide risk; or (7) had previously had an adequate A treatment manual32 modeled after the National Institute trial of MAOIs or cognitive therapy that failed. of Mental Health Treatment of Depression Collaborative 2 cantly more than placebo and that the active treatments (x 2 = 22.04; P#.001). Five patients (14%) dropped out would produce comparable reductions. of cognitive therapy, 9 (25%) from phenelzine, and 23 (64%) from placebo. Attrition in the placebo group was RESULTS significantly greater than in cognitive therapy 2 2 (x 1 = 18.94; P#.001) and phenelzine (x 1 = 11.03; SAMPLE DESCRIPTION P#.001). The attrition between active treatments did 2 not differ significantly (x 1 = 1.42; P = .23). Of patients One hundred forty-two outpatients with MDD and atypi- in cognitive therapy, 1 dropped out before the first
Load more

Recommended publications
  • Dietary Patterns Are Differentially Associated with Atypical and Melancholic Subtypes of Depression
    nutrients Article Dietary Patterns Are Differentially Associated with Atypical and Melancholic Subtypes of Depression Aurélie M. Lasserre 1,* , Marie-Pierre F. Strippoli 1 , Pedro Marques-Vidal 2 , Lana J. Williams 3, Felice N. Jacka 3, Caroline L. Vandeleur 1, Peter Vollenweider 2 and Martin Preisig 1 1 Department of Psychiatry, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; [email protected] (M.-P.F.S.); [email protected] (C.L.V.); [email protected] (M.P.) 2 Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland; [email protected] (P.M.-V.); [email protected] (P.V.) 3 Barwon Health, IMPACT—The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong 3220, Australia; [email protected] (L.J.W.); [email protected] (F.N.J.) * Correspondence: [email protected]; Tel.: +41-21-314-3552 Abstract: Diet has been associated with the risk of depression, whereas different subtypes of depres- sion have been linked with different cardiovascular risk factors (CVRFs). In this study, our aims were to (1) identify dietary patterns with exploratory factor analysis, (2) assess cross-sectional associations between dietary patterns and depression subtypes, and (3) examine the potentially mediating effect of dietary patterns in the associations between CVRFs and depression subtypes. In the first follow-up of the population-based CoLaus|PsyCoLaus study (2009–2013, 3554 participants, 45.6% men, mean age Citation: Lasserre, A.M.; Strippoli, 57.5 years), a food frequency questionnaire assessed dietary intake and a semi-structured interview M.-P.F.; Marques-Vidal, P.; Williams, allowed to characterize major depressive disorder into current or remitted atypical, melancholic, L.J.; Jacka, F.N.; Vandeleur, C.L.; and unspecified subtypes.
    [Show full text]
  • Adult Depression Clinical Practice Guidelines
    NATIONAL CLINICAL PRACTICE GUIDELINE Adult Depression Clinical Practice Guideline This guideline is informational only. It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by practitioners, considering each patient’s needs on an individual basis. Guideline recommendations apply to populations of patients. Clinical judgment is necessary to design treatment plans for individual patients. Approved by the National Guideline Directors February 2012 Table of Contents Introduction................................................................................................................................... 1 Guideline Summary...................................................................................................................... 5 Rationale Statements .................................................................................................................. 12 1. First-Line Treatment of Major Depressive Disorder (MDD) .............................................. 12 2. Hypericum (St. John’s Wort) for MDD............................................................................... 38 3. Antidepressants In Patients With MDD Expressing Suicidal Ideation, Intent, Or Plan...... 44 4. Second-Line Treatment Of MDD ........................................................................................ 48 5. Length Of Treatment With Antidepressants In Patients With MDD................................... 63 6. Follow-Up For Patients In The Acute Phase of Treatment For MDD................................
    [Show full text]
  • A History of the Concept of Atypical Depression
    Jonathan R. T. Davidson A History of the Concept of Atypical Depression Jonathan R. T. Davidson, M.D. The term atypical depression as a preferentially monoamine oxidase inhibitor (MAOI)–responsive state was first introduced by West and Dally in 1959. Further characterization of this syndrome and its responsiveness to antidepressants came to occupy the attention of many psychopharmacologists for the next 30 years. Different portrayals of atypical depression have emerged, for example, nonendoge- nous depression, phobic anxiety with secondary depression, vegetative reversal, rejection-sensitivity, and depression with severe chronic pain. Consistency across or within types has been unimpressive, and no coherent single type of depression can yet be said to be “atypical.” In successfully demonstrat- ing superiority of MAOI drugs to tricyclics, the Columbia (or DSM-IV) criteria have established their utility and become widely adopted, but other criteria have also passed this test. In this “post-MAOI” era, no novel compound or group of drugs has been clearly shown to have good efficacy in atypical depression, leaving the treatment of atypical depression as an unmet need. (J Clin Psychiatry 2007;68[suppl 3]:10–15) DEVELOPING THE CONCEPT drawn from the medication after a few months of treat- OF ATYPICAL DEPRESSION ment. This observation may reflect recovery from brief episodes of depression or possibly a set of patients with The concept of atypical depression with respect to different atypical symptoms than those seen today; it is monoamine oxidase inhibitors (MAOIs) was first articu- also possible that follow-up was not long enough to lated in 1959 by West and Dally1 upon recognizing a sub- observe relapses.
    [Show full text]
  • Double-Blind Switch Study of Imipramine Or Sertraline Treatment of Antidepressant-Resistant Chronic Depression
    ORIGINAL ARTICLE Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression Michael E. Thase, MD; A. John Rush, MD; Robert H. Howland, MD; Susan G. Kornstein, MD; James H. Kocsis, MD; Alan J. Gelenberg, MD; Alan F. Schatzberg, MD; Lorrin M. Koran, MD; Martin B. Keller, MD; James M. Russell, MD; Robert M. A. Hirschfeld, MD; Lisa M. LaVange, PhD; Daniel N. Klein, PhD; Jan Fawcett, MD; Wilma Harrison, MD Background: Although various strategies have been pro- verse effects. Although sertraline treatment also re- posed to treat antidepressant nonresponders, little con- sulted in significantly higher response rates in the intent- trolled research has been published that examines pro- to-treat samples (60% in the sertraline group and 44% spectively the use of switching to an alternate antidepressant. in the imipramine group), neither the intent-to-treat re- mission rates nor the response and remission rates among Methods: This was a multisite study in which outpa- study completers differed significantly. Moreover, after tients with chronic major depression (with or without considering the effect of attrition, there were no signifi- concurrent dysthymia), who failed to respond to 12 weeks cant treatment effects on the more comprehensive gen- of double-blind treatment with either sertraline hydro- eralized estimating equation analyses of the continuous chloride (n=117) or imipramine hydrochloride (n=51), dependent measures. were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication. Conclusions: More than 50% of chronically depressed Outcome measures included the 24-item Hamilton Rat- antidepressant nonresponders benefited from a switch ing Scale for Depression and the Clinical Global Impres- from imipramine to sertraline, or vice versa, despite a high sions–Severity and Improvement scales.
    [Show full text]
  • Affective Disorders and Antidepressant Drugs
    Open Access Library Journal Affective Disorders and Antidepressant Drugs Marc Fakhoury Department of Neuroscience, Faculty of Medicine, University of Montreal, Montreal, Canada Email: [email protected] Received 4 June 2014; revised 10 July 2014; accepted 18 August 2014 Copyright © 2014 by author and OALib. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Affective disorders are a group of psychiatric diseases that can affect an individual at any given age. Also called mood disorders, they can be distinguished into two different types: major depres- sive disorder, also called major depression, and bipolar disorder, which is known as manic de- pression. People affected by major depression most often have a low mood, and are consistently in a state of unhappiness. Although it was shown that genetics play a role in the predisposition of depression, this disease most often occurs in response to a variety of external factors such as a stressful life event, the loss of a loved one, and following drug or substance abuse. A variety of an- tidepressant drugs, such as the monoamine oxidase inhibitors (MAOIs), the tricyclic antidepres- sants (TCAs), and the second-generation antidepressants are able to provide significant relief for people suffering from affective disorders like depression. However, several of these pharma- ceutical agents can cause serious side effects to the patients. Therefore, there is a need to identify novel antidepressant therapies that are more efficient and that present minimal side effects. A better understanding of the neurobiology of depression will definitively help scientists develop new therapeutic ideas.
    [Show full text]
  • DBSA Uni Bipolar.V2:DBSA Findadocfinal
    Mood Disorders and Different Kinds of Depression We’ve been there. We can help. n any given year, nearly one in 10 American I adults will suffer from a mood disorder. These ill- nesses involve changes in mood that affect daily life. They include major depres- sive disorder, dysthymia (persistent, low-grade depression) and bipolar disorder (episodes of “low” mood that alternate with episodes of “high” mood or unusual levels of energy or activity). People with mood disorders might have trouble with work life, family life and social life, or they might have difficulty simply get- ting through the day. While most mood disorders have depression in common, only in bipolar disorder are there mood swings of depression and periods of hypo- mania (if the bipolar disorder is mild) or mania (if severe). It’s important to know the difference between the different types of depression, because different types require different treatments. What is Depression? Depression is more than just feeling sad. It’s a seri- ous—but treatable—medical illness characterized by an imbalance of brain chemicals called neurotransmitters and neuropeptides. It’s not a character flaw or a sign of personal weakness. Just like you can’t “wish away” dia- betes, heart disease or any other physical illness, you can’t make depression go away by trying to “snap out of it” or “pull yourself up by your boot straps.” Early in people’s experience of a mood disorder, their episodes of depression often follow stressful events like marital problems or the death of a loved one. While depression sometimes runs in families, many with the illness have no family history of depression.
    [Show full text]
  • A Practical Approach to Subtyping Depression Among Your Patients
    SECOND OF 2 PARTS A practical approach to subtyping depression among your patients Improve outcomes by understanding the forms that depressive disorders can take epression—sad, empty, or irritable mood accompanied by somatic or cognitive changes—is not a homoge- Dneous condition. Recognizing subtypes of depressive illness can guide treatment and relieve your patient’s suf- fering. In this 2-part article [April and May 2014 issues], I summarize information about clinically distinct subtypes of depression, as they are recognized within diagnostic systems or as descriptors of treatment outcomes for particular sub- groups of patients. My focus is on practical considerations for assessing and managing depression. Because many forms of the disorder respond inadequately to initial antidepressant treatment, optimal “next-step” pharmacotherapy, after nonre- sponse or partial response, often hinges on clinical subtyping. JON KRAUSE/THE ISPOT.COM The second part of this article examines “situational,” treat- ment-resistant, melancholic, agitated, anxious, and atypical Joseph F. Goldberg, MD depression; depression occurring with a substance use disor- Clinical Professor of Psychiatry Icahn School of Medicine at Mount Sinai der; premenstrual dysphoric disorder; and seasonal affective New York, New York disorder. Treatments for these subtypes for which there is evi- Director, Affective Disorders Research Program dence, or a clinical rationale, are given in the Table, page 42. Silver Hill Hospital New Canaan, Connecticut ‘Situational’ depression In recent decades, the phenomenon of nonsyndromal depres- sion after a life stress has undergone many name changes but lit- tle conceptual revision: “situational,” “reactive,” and “neurotic” labels for depression that were used before DSM-III became “adjustment disorders” in DSM-IV-TR and then “stress Disclosure Dr.
    [Show full text]
  • Predicting Relapse After Antidepressant Withdrawal – a Systematic Review
    Psychological Medicine (2017), 47, 426–437. © Cambridge University Press 2016 REVIEW ARTICLE doi:10.1017/S0033291716002580 Predicting relapse after antidepressant withdrawal – a systematic review I. M. Berwian1,2*, H. Walter3, E. Seifritz1 and Q. J. M. Huys1,2 1 Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Lenggstrasse 31, 8032 Zürich, Switzerland 2 Translational Neuromodeling Unit, Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Wilfriedstrasse 6, 8032 Zürich, Switzerland 3 Mind and Brain, Campus Charité Mitte, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany A substantial proportion of the burden of depression arises from its recurrent nature. The risk of relapse after antidepres- sant medication (ADM) discontinuation is high but not uniform. Predictors of individual relapse risk after antidepressant discontinuation could help to guide treatment and mitigate the long-term course of depression. We conducted a system- atic literature search in PubMed to identify relapse predictors using the search terms ‘(depress* OR MDD*) AND (relapse* OR recurren*) AND (predict* OR risk) AND (discontinu* OR withdraw* OR maintenance OR maintain or con- tinu*) AND (antidepress* OR medication OR drug)’ for published studies until November 2014. Studies investigating predictors of relapse in patients aged between 18 and 65 years with a main diagnosis of major depressive disorder (MDD), who remitted from a depressive episode while treated with ADM and were followed up for at least 6 months to assess relapse after part of the sample discontinued their ADM, were included in the review. Although relevant in- formation is present in many studies, only 13 studies based on nine separate samples investigated predictors for relapse after ADM discontinuation.
    [Show full text]
  • Management of Major Depressive Disorder(MDD)
    ClinicalPracticeGuideline SUMMARY Managementof MajorDepressiveDisorder(MDD) May,2009 VA/DoDEvidenceBasedPractice VA/DoD CLINICAL PRACTICE GUIDELINE FOR MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Department of Veterans Affairs Department of Defense SUMMARY QUALIFYING STATEMENTS The Department of Veterans Affairs (VA) and The Department of Defense (DoD) guidelines are based on the best information available at the time of publication. They are designed to provide information and assist in decision-making. They are not intended to define a standard of care and should not be construed as one. Also, they should not be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when providers take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of these guidelines is responsible for evaluating the appropriateness of applying them in any particular clinical situation. Version 2.0 – 2008 VA/DoD Clinical Practice Guideline For Management of Major Depressive Disorder Table of Contents Page Introduction 1 Guideline Update Working Group 3 Key Elements Addressed by the Guideline 4 Algorithms and Annotations 6 Appendices Appendix A: Guideline Development process (See full guideline) Appendix B: Screening and Assessment Instruments B-1. Quick Guide to the Patient Health Questionnaire (PHQ) B-2. Example of Diagnosing MDD & Calculating PHQ-9 Score B-3. PHQ-9 Scores and Proposed Treatment Actions B-4. Nine Symptom Checklist (PHQ-9) Appendix C: Suicidality (See full guideline) Appendix D: Pharmacotherapy D- 1. Antidepressant Dosing and Monitoring D-2. Antidepressant Adverse Effects Appendix E: Participants list (See full guideline) Appendix F: Acronym List Appendix G: Bibliiography (See full guideline) Table of Contents VA/DoD Clinical Practice Guideline For Management of Major Depressive Disorder Introduction Major Depressive Disorder (MDD) Depression is a major cause of disability worldwide.
    [Show full text]
  • The ICD-10 Classification of Mental and Behavioural Disorders
    The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines World Health Organization -1- Preface In the early 1960s, the Mental Health Programme of the World Health Organization (WHO) became actively engaged in a programme aiming to improve the diagnosis and classification of mental disorders. At that time, WHO convened a series of meetings to review knowledge, actively involving representatives of different disciplines, various schools of thought in psychiatry, and all parts of the world in the programme. It stimulated and conducted research on criteria for classification and for reliability of diagnosis, and produced and promulgated procedures for joint rating of videotaped interviews and other useful research methods. Numerous proposals to improve the classification of mental disorders resulted from the extensive consultation process, and these were used in drafting the Eighth Revision of the International Classification of Diseases (ICD-8). A glossary defining each category of mental disorder in ICD-8 was also developed. The programme activities also resulted in the establishment of a network of individuals and centres who continued to work on issues related to the improvement of psychiatric classification (1, 2). The 1970s saw further growth of interest in improving psychiatric classification worldwide. Expansion of international contacts, the undertaking of several international collaborative studies, and the availability of new treatments all contributed to this trend. Several national psychiatric bodies encouraged the development of specific criteria for classification in order to improve diagnostic reliability. In particular, the American Psychiatric Association developed and promulgated its Third Revision of the Diagnostic and Statistical Manual, which incorporated operational criteria into its classification system.
    [Show full text]
  • Treatment-Induced Manic Switch in the Course of Unipolar Depression Can Predict Bipolarity: Cluster Analysis Based Evidence
    JAD-05110; No of Pages 11 Journal of Affective Disorders xxx (2011) xxx–xxx Contents lists available at ScienceDirect Journal of Affective Disorders journal homepage: www.elsevier.com/locate/jad Research report Treatment-induced manic switch in the course of unipolar depression can predict bipolarity: Cluster analysis based evidence Kemal Dumlu a,1, Zahide Orhon a,2,Ayşegül Özerdem a,b,c,d, Ümit Tural e, Halis Ulaş a, Zeliha Tunca a,⁎ a Dokuz Eylul University, School of Medicine, Department of Psychiatry Izmir, Turkey b Department of Neuroscience, Dokuz Eylul University Health Sciences Institute Izmir, Turkey c Multidisciplinary Brain Dynamics Research Center, Dokuz Eylul University Izmir, Turkey d Kültür University, Brain Dynamics, Cognition, and Complex Systems Research Center, Istanbul, Turkey e Kocaeli University, School of Medicine, Department of Psychiatry, Kocaeli, Turkey article info abstract Article history: Background: Antidepressants are known to induce manic switch in patients with depression. Received 11 April 2011 Treatment-induced mania is not considered as bipolar disorder in DSM IV. The aim of this study Received in revised form 16 June 2011 was to assess whether clinical characteristics of patients with unipolar depression with a Accepted 16 June 2011 history of treatment-induced mania were similar to those of patients with bipolar disorder. Available online xxxx Method: The study included 217 consecutive patients with DSM-IV mood disorders, diagnosed as: bipolar disorder type I (BP-I, n=58) or type II (BP-II, n=18) whose first episodes were Keywords: depression, recurrent (unipolar) major depressive disorder with a history of antidepressant Bipolar disorder Recurrent depression treatment-induced mania (switchers=sUD; n=61) and without such an event (rUD; n=80).
    [Show full text]
  • Partial Validation of the Atypical Features Subtype of Major Depressive Disorder
    ORIGINAL ARTICLE Partial Validation of the Atypical Features Subtype of Major Depressive Disorder Michael A. Posternak, MD; Mark Zimmerman, MD Background: Symptoms of the atypical features sub- semistructured interviews. Using the available litera- type of major depressive disorder include mood reactiv- ture, we made a series of a priori hypotheses regarding ity, hypersomnia, hyperphagia, leaden paralysis, and re- how depressed patients with atypical features (n=130) jection sensitivity. This subtype was introduced into the would differ from those without atypical features (n=449). mood disorders section of the DSM-IV following a series In addition, we tested the strength of the associations be- of antidepressant trials showing that such patients re- tween each of the 5 atypical symptoms. sponded preferentially to monoamine oxidase inhibi- tors. Studies aimed at validating the atypical features sub- Results: Although many of the predicted hypotheses were type have yielded inconsistent results. Our study sought substantiated, an equal number were not. Correlation to reevaluate the validity of atypical depression by ex- analyses revealed modest associations between several of amining the demographic and clinical features of a large the atypical symptoms, but mood reactivity was not as- cohort of depressed patients who met DSM-IV criteria for sociated with any of the other symptom criteria. atypical features. Conclusion: Our results provide partial support for the Methods: We evaluated 579 psychiatric outpatients with validity of the atypical features subtype of major depres- a current diagnosis of major depressive disorder for the sive disorder. presence of atypical features. Detailed demographic and clinical information was obtained for each patient through Arch Gen Psychiatry.
    [Show full text]